检测肿瘤组织和血液以帮助为疑似肺癌患者选择个性化治疗
LEADER 新辅助筛选试验:LCMC4 评估早期肺癌的可操作驱动因素
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.
The primary purpose of this testing is to determine the presence of 12 oncogenic drivers (mutations in EGFR, BRAFV600E , MET exon 14, KRAS G12C and HER2, rearrangements in ALK, RET, NTRK, EGFR exon 20 insertion and ROS1, and amplification of MET and HER2) that can serve as targets making patients eligible for upcoming targeted neoadjuvant therapy trials. The ultimate goal is to use this information from the screening process to select the optimal neoadjuvant therapy and wherever possible enroll patients onto separate neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no actionable driver mutation is detected.
Thoracic Surgery Oncology Group (TSOG) is a network of surgeons within North American Thoracic Surgery Academic Centers aligned with the goal of enhancing patient care through administration of multi-site trials focused on recent advances in lung cancer. TSOG has aligned with the LCMC4 sites to enroll the LCRF-LEADER screening trial. TSOG's involvement will be essential in trial enrollment and ultimate interpretation of the multimodal clinical and translational data collected as part of this study. We estimate we will detect an actionable oncogenic driver in 33% of cases. The remaining 66% of patients will represent a cohort identified by their care teams as candidates for other potential neoadjuvant therapies which may include checkpoint inhibitors such as atezolizumab, durvalumab, nivolumab, and pembrolizumab or other novel agents.
The targeted therapy treatment trials will be conducted independently of the LCRF-LEADER screening trial, evaluating for efficacy. If none of the 10 oncogenic drivers are detected, the patient will be offered participation in any clinical trial of neoadjuvant therapy available at their treating institution or standard of care therapy. For patients not enrolled on a targeted treatment trial, circulating tumor DNA in blood (ctDNA) will be collected at 3 time points: before neoadjuvant treatment, after neoadjuvant treatment but before surgery, and after surgery. This initiative will be correlated with various clinical outcomes. Prespecified clinical data will be collected for correlation with these circulating biomarkers.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Christian Brodala, BBA
- 电话号码:646-608-2838
- 邮箱:brodalac@mskcc.org
学习地点
-
-
California
-
Davis、California、美国、95616
- 主动,不招人
- University of California, Davis
-
Los Angeles、California、美国、90095
- 主动,不招人
- UCLA
-
Los Angeles、California、美国、90033
- 撤销
- USC Norris Comprehensive Cancer Center
-
Orange、California、美国、92868
- 招聘中
- St. Joseph's Hospital Orange
-
接触:
- Ron Bati
- 邮箱:Ron.Bati@stjoe.org
-
首席研究员:
- Tiimothy Byun, MD
-
Stanford、California、美国、94305
- 招聘中
- Stanford University
-
接触:
- Debbie Bajomo
- 邮箱:bajomo@stanford.edu
-
首席研究员:
- Douglas Liou, MD
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- 招聘中
- Hartford Healthcare
-
接触:
- Lorin Campos
- 邮箱:lorin.campos@hhchealth.org
-
接触:
- Corey Glider
- 邮箱:Corey.Glider@hhchealth.org
-
首席研究员:
- Brian Whang, MD, FACS
-
-
Florida
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
首席研究员:
- Andreas Saltos, MD
-
接触:
- Tara Ackerman
- 邮箱:Tara.Ackerman@moffitt.org
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern University
-
首席研究员:
- Jyoti Patel, MD
-
接触:
- RHLCCC Trial Team
- 邮箱:RHLCCCTrialStartup@northwestern.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Brigham and Women's Hospital
-
接触:
- Kristina Sidopoulos
- 邮箱:ksidopoulos@bwh.harvard.edu
-
首席研究员:
- Hisashi Tsukada, MD, PhD
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital
-
首席研究员:
- Michael Lanuti, MD
-
接触:
- Isha Mehta Warikoo
- 邮箱:imehtawarikoo@mgh.harvard.edu
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
首席研究员:
- David Kwiatkowski, MD
-
接触:
- Jennifer Luu
- 邮箱:jennifer_luu@dfci.harvard.edu
-
Boston、Massachusetts、美国、02215
- 招聘中
- Beth Israel Deaconess Medical Center
-
接触:
- Christine Conley
- 邮箱:Cconley@bidmc.harvard.edu
-
首席研究员:
- Sidhu Gangadharan, MD
-
Boston、Massachusetts、美国、02118
- 招聘中
- Boston Medical Center
-
接触:
- Anthony Shelton
- 邮箱:anthony.shelton@bmc.org
-
首席研究员:
- Umit Tapan, MD
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan
-
接触:
- Shari Barnett
- 邮箱:shbailey@med.umich.edu
-
首席研究员:
- Jules Lin, MD
-
-
Missouri
-
Columbia、Missouri、美国、65212
- 招聘中
- University of Missouri
-
接触:
- Brooke McDaniel
- 邮箱:mcdanielbl@health.missouri.edu
-
首席研究员:
- Jussuf Kaifi, MD
-
St Louis、Missouri、美国、63110
- 主动,不招人
- Washington University
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- 招聘中
- Dartmouth-Hitchcock
-
接触:
- Kristina Wiley
- 邮箱:Kristina.M.Willey@hitchcock.org
-
首席研究员:
- David Finley, MD
-
-
New York
-
New York、New York、美国、10032
- 主动,不招人
- Columbia University
-
New York、New York、美国、10016
- 招聘中
- NYU
-
首席研究员:
- Elaine Shum, MD
-
接触:
- Nadia Catti
- 邮箱:nadia.catti@nyulangone.org
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University
-
接触:
- Helena Gastier
- 邮箱:Helena.gastier@osumc.edu
-
首席研究员:
- Desmond D'Souza, MD
-
-
Oregon
-
Portland、Oregon、美国、97213
- 招聘中
- Providence Portland
-
首席研究员:
- Rachel Sanborn, MD
-
接触:
- Brenda Fisher
- 邮箱:brenda.fisher@providence.org
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- Medical University of South Carolina
-
接触:
- Jessica Shealor
- 邮箱:shealorj@musc.edu
-
首席研究员:
- Ian Bostock, MD
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- Baylor College of Medicine
-
接触:
- Michelle Almarez
- 邮箱:michelle.almarez@bcm.edu
-
首席研究员:
- Taylor Ripley, MD
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists, PC
-
首席研究员:
- Alexander Spira, MD, PhD, FACP
-
接触:
- Brian Phipps
- 邮箱:Brian.phipps@usoncology.com
-
-
Washington
-
Seattle、Washington、美国、98019
- 招聘中
- University of Washington
-
接触:
- Lara Schiff
- 邮箱:lschiff1@seattlecca.org
-
首席研究员:
- Christina Baik, MD, MPH
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The LCMC LEADER screening trial will enroll all patients with clinically suspected, resectable stage I-III lung cancers. The population of interest is patients with resectable non-squamous non-small cell lung cancer, however a histologic diagnosis is not required at the time of study enrollment. We anticipate a small portion of patients with squamous cell and non-NSCLC histologies to be genotyped centrally in parallel to their histologic diagnosis. Only patients with non-small cell lung cancers that are not purely squamous will be counted towards the primary study endpoint.
描述
Inclusion Criteria:
- Clinical stage IA2-III lung cancers
- Potentially resectable if lung cancer suspicion confirmed pathologically
- Operable
Exclusion Criteria:
- No concurrent malignancy
- No prior lung cancer within last 2 years
- Purely ground glass pulmonary opacity
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Patients who Possess Actionable Oncogenic Drivers
大体时间:8 weeks
|
The primary outcome measure is the determination of the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. A patient is considered to have a actionable oncogenic driver if they have any of the following 10 genomic alterations: ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, or ROS1 rearrangements. |
8 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Tumor Mutation Burden (TMB) Assessment
大体时间:8 weeks
|
Measure TMB in all patient tumor samples (Mutations per megabase) |
8 weeks
|
合作者和调查者
调查人员
- 首席研究员:Michael Lanuti, MD、Massachusetts General Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- LCMC LEADER
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.